CSPG4 and breast cancer: In contrast, several preclinical studies on the remaining ten cell surface protein targets (CD133, MUC1, MSLN, CD70, EpCAM, CSPG4, ICAM-1, TEM8, TROP2, FRα) have shown potential as CAR-T targets for the treatment of BC [180–189].